ReviewACS omega2026
From Unlocking Pyruvate Hyperpolarization by Signal Amplification by Reversible Exchange (SABRE) to Clinical Prospects.
Review in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- IrTMes - a stable SABRE catalyst for the hyperpolarization of [1-The Analyst · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyperpolarization in magnetic resonance has emerged as a transformative approach to overcome the intrinsic sensitivity limits of NMR and MRI. Among the accessible hyperpolarization methods, Signal Amplification by Reversible Exchange (SABRE) has attracted considerable attention due to its rapidity, simplicity, and low operational cost. However, extending SABRE to biologically relevant metabolites notably pyruvate, remained challenging because carboxylates do not bind to the iridium-based catalysts. Over the past decade, series of mechanistic insights, catalyst innovations, and field-cycling strategies have been developed to redefin the hyperpolarization landscape, enabling robust SABRE-based polarization of
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.